Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of an experimental drug (p28) as a
treatment for certain advanced cancers which express a protein called p53 and which have not
responded to prior treatment.